KUBOTA PHARMACEUTICAL HOLDINGS CO LTD
ACUC evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Lead Asset:
- acu-6151 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ACUC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
acu-6151 (Preclinical)
Next Catalyst
—
Tracking 3 pipeline candidates for KUBOTA PHARMACEUTICAL HOLDINGS CO LTD.
Run KUBOTA PHARMACEUTICAL HOLDINGS CO LTD through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available KUBOTA PHARMACEUTICAL HOLDINGS CO LTD facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is KUBOTA PHARMACEUTICAL HOLDINGS CO LTD's lead drug candidate?
KUBOTA PHARMACEUTICAL HOLDINGS CO LTD's most advanced tracked candidate is acu-6151 (Preclinical) for neovascular retinal diseases such as wet age related macular degeneration, diabetic retinopathy / diabetic macular edema and retinal vein occlusion.
Who is the CEO of KUBOTA PHARMACEUTICAL HOLDINGS CO LTD?
Board Table is the chief executive officer of KUBOTA PHARMACEUTICAL HOLDINGS CO LTD (ACUC).
What therapeutic areas does KUBOTA PHARMACEUTICAL HOLDINGS CO LTD focus on?
KUBOTA PHARMACEUTICAL HOLDINGS CO LTD develops therapies across Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.